Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 6,693 Shares of Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 6,693 shares of the firm’s stock in a transaction that occurred on Friday, January 30th. The stock was sold at an average price of $40.09, for a total transaction of $268,322.37. Following the transaction, the chief executive officer directly owned 31,980 shares of the company’s stock, valued at approximately $1,282,078.20. This trade represents a 17.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Jack Bendheim also recently made the following trade(s):

• On Thursday, January 29th, Jack Bendheim sold 6,772 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.12, for a total value of $271,692.64.
• On Friday, January 23rd, Jack Bendheim sold 1,235 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.55, for a total value of $50,079.25.
• On Thursday, January 22nd, Jack Bendheim sold 13,158 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.98, for a total value of $552,372.84.
• On Wednesday, January 21st, Jack Bendheim sold 14,687 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.68, for a total value of $612,154.16.
• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.02, for a total transaction of $117,338.64.
• On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.53, for a total transaction of $147,975.03.
• On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.32, for a total transaction of $304,456.32.
• On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.16, for a total transaction of $8,554.08.
• On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total transaction of $13,149.52.
• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.93, for a total transaction of $235,429.36.

Phibro Animal Health Trading Up 4.4%

PAHC traded up $1.76 during trading on Monday, hitting $41.91. The company’s stock had a trading volume of 217,182 shares, compared to its average volume of 192,145. The stock has a market cap of $1.70 billion, a PE ratio of 25.25, a PEG ratio of 1.14 and a beta of 0.79. The company has a debt-to-equity ratio of 2.32, a current ratio of 3.09 and a quick ratio of 1.35. Phibro Animal Health Corporation has a twelve month low of $16.16 and a twelve month high of $46.42. The firm’s 50 day moving average price is $39.87 and its 200-day moving average price is $37.87.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.15. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.The firm had revenue of $363.89 million for the quarter, compared to the consensus estimate of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. On average, analysts expect that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, December 17th. Investors of record on Wednesday, November 26th were issued a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date was Wednesday, November 26th. Phibro Animal Health’s payout ratio is presently 28.92%.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Weiss Ratings reissued a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 9th. Finally, JPMorgan Chase & Co. upped their price target on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Phibro Animal Health has a consensus rating of “Hold” and a consensus price target of $31.40.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of PAHC. Tudor Investment Corp ET AL raised its holdings in shares of Phibro Animal Health by 3.4% during the 3rd quarter. Tudor Investment Corp ET AL now owns 10,184 shares of the company’s stock valued at $412,000 after buying an additional 338 shares during the period. JPMorgan Chase & Co. grew its position in Phibro Animal Health by 2.9% in the second quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock valued at $332,000 after acquiring an additional 363 shares in the last quarter. Farther Finance Advisors LLC raised its stake in shares of Phibro Animal Health by 113.2% during the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after purchasing an additional 386 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Phibro Animal Health by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock worth $260,000 after purchasing an additional 546 shares in the last quarter. Finally, Prospera Financial Services Inc boosted its stake in shares of Phibro Animal Health by 3.6% in the second quarter. Prospera Financial Services Inc now owns 19,910 shares of the company’s stock valued at $508,000 after purchasing an additional 690 shares during the period. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.